Advertisement

Advertisement

ADVERTISEMENT

Dermatology Advances Basic Listing

Risankizumab Achieved Superiority Vs Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis

Upadacitinib Approved For Adults and Children Aged 12 Years and Older With Refractory, Moderate to Severe Atopic Dermatitis

Tildrakizumab Presented Consistent Reduction of Detectable Psoriasis Through 5 Years

Risankizumab: The Only IL-23 Inhibitor FDA-Approved for Adults with Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis

Newer IL-23 Inhibitor Demonstrates Improvement in Nail, Scalp, and Palmoplantar Psoriasis

Tildrakizumab Shows Sustained Efficacy, Safety Over a 5-Year Period for Moderate to Severe Plaque Psoriasis

Patients Receiving Risankizumab Report Immediate and Sustained Improvements in Severity, HRQL, and Mental Health in Two Phase 3 Clinical Trials

Risankizumab Demonstrates Superiority for Treatment of Adults with Moderate to Severe Plaque Psoriasis in Head-to-head Phase 3 Trial

Dermatology Advances Updates

Dr Farberg on Tildrakizumab

Videos

Insights on Tildrakizumab: Durability and Safety

07/09/2021

In this video Dr Farberg discusses his insights on tildrakizumab’s durability and safety following his poster presentation at AAD 2021.

In this video Dr Farberg discusses his insights on tildrakizumab’s durability and safety following his poster presentation at AAD 2021.

In this video Dr Farberg...

07/09/2021

The Dermatologist

Dr Blauvelt on Improvements in Safety in Biologic Therapies

Videos

Dr Blauvelt on Improvements in Safety in Biologic Therapies

08/13/2020

In the video below, Andrew Blauvelt, MD, MBA, discusses how the thought on safety with biologic use has changed over the years.

In the video below, Andrew Blauvelt, MD, MBA, discusses how the thought on safety with biologic use has changed over the years.

In the video below, Andrew...

08/13/2020

The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement